β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma

  • Authors:
    • Zheng Wang
    • Yuan‑Yuan Sheng
    • Xiao‑Mei Gao
    • Chao‑Qun Wang
    • Xiang‑Yu Wang
    • Xu Lu
    • Jin‑Wang Wei
    • Kai‑Li Zhang
    • Qiong‑Zhu Dong
    • Lun‑Xiu Qin
  • View Affiliations

  • Published online on: May 15, 2015     https://doi.org/10.3892/mco.2015.569
  • Pages: 936-940
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The β-catenin gene is frequently mutated in patients with hepatocellular carcinoma (HCC) and has long been thought to be one of the major oncogenes involved in the hepatocarcinogenesis. The prognostic role of β‑catenin mutation in HCC remains unclear. To address this issue, a search for relevant studies was performed in the PubMed, Embase and Web of Science databases. The pooled effect was calculated from the available data to evaluate the correlation of β‑catenin mutation with overall survival rate and tumor clinicopathological features in patients with HCC. The pooled odds ratio (OR) was calculated using the Mantel‑Haenszel model for fixed effects. Three studies met the inclusion criteria. A total of 618 cases were included, and β‑catenin mutation was identified in 104 of them. The meta‑analysis revealed that the presence of β‑catenin mutation (n=104), compared with the control group (n=514), was correlated with a longer overall survival rate [OR, 0.33; 95% confidence interval (CI), 0.21‑0.53; P<0.00001] in patients with HCC. No significant heterogeneity was found among the eligible studies (I2=0%; P=0.72). β‑catenin mutation was correlated with a relatively lower rate of hepatitis B virus infection (OR, 0.36; 95% CI, 0.21‑0.61; P=0.0002), improved tumor differentiation (OR, 0.32; 95% CI, 0.19‑0.56; P<0.0001) and a lower tumor‑node‑metastasis stage (I+II) (OR, 0.23; 95% CI, 0.14‑0.38; P<0.00001). These findings suggest that β‑catenin mutation may predict a favorable prognosis in patients with HCC.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 3 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Z, Sheng YY, Gao XM, Wang CQ, Wang XY, Lu X, Wei JW, Zhang KL, Dong QZ, Qin LX, Qin LX, et al: β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol 3: 936-940, 2015.
APA
Wang, Z., Sheng, Y., Gao, X., Wang, C., Wang, X., Lu, X. ... Qin, L. (2015). β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Molecular and Clinical Oncology, 3, 936-940. https://doi.org/10.3892/mco.2015.569
MLA
Wang, Z., Sheng, Y., Gao, X., Wang, C., Wang, X., Lu, X., Wei, J., Zhang, K., Dong, Q., Qin, L."β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma". Molecular and Clinical Oncology 3.4 (2015): 936-940.
Chicago
Wang, Z., Sheng, Y., Gao, X., Wang, C., Wang, X., Lu, X., Wei, J., Zhang, K., Dong, Q., Qin, L."β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma". Molecular and Clinical Oncology 3, no. 4 (2015): 936-940. https://doi.org/10.3892/mco.2015.569